Drugs / Hutrukin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05098080 Comparator | Apr → Oct 2023 | — | XBiotech, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hutrukin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05098080 ↗ |
| Known as | HutrukinTM | “The study will be a Phase I, open label, safety and pharmacokinetics study of HutrukinTM in at least eight healthy subjects in each of the three dose cohorts (1,000 mg, 3,000...” NCT05098080 ↗ |
| Action | Inhibit | “Hutrukin that binds the human cytokine IL-1α with high affinity and is an effective blocker of IL-1α biological activity.” NCT05098080 ↗ |
| Route | Intravenous | “one intravenous push of Hutrukin” NCT05098080 ↗ |